All In Biotech

Drug Trial Radar · NCT07855016

A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma

A Multicenter, Open-Label, Phase II Dose-Exploration and Expansion Study to Evaluate TT-01488 Tablets in Combination With an Anti-CD20 Monoclonal Antibody-Containing Regimen for the Treatment of Mantle Cell Lymphoma.

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Oct 10, 2029

Study completion Oct 10, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase II study evaluating TT-01488 in combination with different anti-CD20 monoclonal antibody-containing regimens for the treatment of treatment-naïve mantle cell lymphoma (MCL).

Conditions

  • Mantle Cell Lymphoma (MCL)

Interventions

  • TT-01488 TabletsDrug

    Oral

  • RituximabDrug

    Intravenous Injection (IV)

  • Immunomodulatory AgentDrug

    Oral

  • BCL2 InhibitorDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Part B Complete Response Rate (CRR) After 6 Cycles of Induction TherapyTime frame: After 6 cycles of induction therapy (each cycle is 28 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.